Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy

Autor: Jorge E. Cortes, Florian H. Heidel, Walter Fiedler, B. Douglas Smith, Tadeusz Robak, Pau Montesinos, Anna Candoni, Brian Leber, Mikkael A. Sekeres, Daniel A. Pollyea, Roxanne Ferdinand, Weidong Wendy Ma, Thomas O’Brien, Ashleigh O’Connell, Geoffrey Chan, Michael Heuser

Publikováno v: Journal of Hematology & Oncology, Vol 13, Iss 1, Pp 1-12 (2020)

Abstract Background The phase 2 BRIGHT AML 1003 trial evaluated efficacy and safety of glasdegib + low-dose cytarabine (LDAC) in patients with acute myeloid leukemia ineligible for intensive chemotherapy. The multicenter, open-label study randomized

Externí odkaz: https://doaj.org/article/eb1cbed6f88d4b89add1a17240cfd403

SuppData from Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS

Autor: Jorge E. Cortes, Geoffrey Chan, Ashleigh O'Connell, Mirjana Zeremski, A. Douglas Laird, M. Naveed Shaik, Weidong Wendy Ma, Hagop M. Kantarjian, James McCloskey, Jeffrey Lancet, Mark A. Schroeder, Vivian G. Oehler, Wendy Stock, Daniel A. Pollyea, Michael R. Savona

Additional Methods: MTD determination; Biomarker analyzed Supplementary Table S1. Patient disposition by treatment group Supplementary Table S2. Treatment-related AEs reported in >10% of patients in arm A Supplementary Table S3. Treatment-related AEs

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::030fa3fc24f2ed0aaede5e6bfe9fd078
https://doi.org/10.1158/1078-0432.22464449

Magnetismm-4: An Open Label, Phase 1B/2 Umbrella Study of Elranatamab in Combination with Other Anti-Cancer Treatments for Patients with Multiple Myeloma

Autor: Ola Landgren, Dickran Kazandjian, Ashleigh O'Connell, Gregory Finn, Noopur Raje

Publikováno v: Blood. 140:10172-10173

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::690a40ea58985de24b378252f97b8248
https://doi.org/10.1182/blood-2022-166854

Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy

Autor: Geoffrey Chan, Thomas O’Brien, Brian Leber, Mikkael A. Sekeres, Roxanne Ferdinand, Jorge E. Cortes, Tadeusz Robak, Weidong Wendy Ma, Michael Heuser, Florian H. Heidel, Pau Montesinos, Daniel A. Pollyea, B. Douglas Smith, Ashleigh O'Connell, Walter Fiedler, Anna Candoni

Publikováno v: Journal of Hematology & Oncology
JOURNAL OF HEMATOLOGY & ONCOLOGY
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
Journal of Hematology & Oncology, Vol 13, Iss 1, Pp 1-12 (2020)

Background The phase 2 BRIGHT AML 1003 trial evaluated efficacy and safety of glasdegib + low-dose cytarabine (LDAC) in patients with acute myeloid leukemia ineligible for intensive chemotherapy. The multicenter, open-label study randomized patients

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e805986714f1d8ebfe7b71ee726cf25c
https://doi.org/10.1186/s13045-020-00929-8

AML-140: Effect of Early Blood Counts on Response and Overall Survival Following Glasdegib Plus LDAC in Newly Diagnosed AML: BRIGHT AML 1003 Post Hoc Analysis

Autor: Ashleigh O'Connell, Eunice S. Wang, Geoffrey Chan, Jorge E. Cortes, Anna Candoni, Cristina Papayannidis, Andrew Brown, Akil Merchant, Mikkael A. Sekeres, Michael Heuser, Weidong Wendy Ma

Publikováno v: Clinical Lymphoma Myeloma and Leukemia. 20:S184

Context The BRIGHT AML 1003 randomized phase 2 study ( NCT01546038 ) compared glasdegib (GLAS) plus LDAC vs LDAC-alone in patients with newly diagnosed AML or high-risk MDS who were ineligible for intensive chemotherapy. Addition of GLAS to LDAC appr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c1e02a7d951e96323cc61efd61b756a1
https://doi.org/10.1016/s2152-2650(20)30720-5